Additionally, when combined with ICI treatment, such as anti PD-L1, M1-derived nanovesicles further enhanced anti-tumor efficiency, as evidenced by a greater reduction in tumor size and elevated apoptosis compared to the treatment with either M1 nanovesicles or anti PD-L1 alone (Figure 5B) [133]. This evidence concerns the gene CD274 and neoplasm.